Biogen (BIIB) Change in Receivables (2009 - 2026)

Biogen has reported Change in Receivables for 18 years, with the latest figure at $269.4 million in Q2 2026.

• On a quarterly basis, Change in Receivables rose 2665.71% year-over-year to $269.4 million in Q2 2026; TTM through Jun 2026 was -$107.2 million, a 60.24% decrease from a year earlier, with the FY2025 full-year figure at -$102.7 million, up 53.8% from the prior year.
• Change in Receivables was $269.4 million for Q2 2026 at Biogen, up from -$103.4 million in the prior quarter.
• The five-year high for Change in Receivables was $269.4 million in Q2 2026, with the low at -$245.4 million in Q3 2025.
• Average Change in Receivables over 5 years is -$938888.9, with a median of -$15.4 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2026: Change in Receivables slumped 246.75% in 2023, then surged 2665.71% in 2026.
• Over 5 years, Change in Receivables stood at $93.9 million in 2022, then plunged by 246.75% to -$137.8 million in 2023, then soared by 31.28% to -$94.7 million in 2024, then surged by 70.64% to -$27.8 million in 2025, then jumped by 1069.06% to $269.4 million in 2026.
• The last three Change in Receivables figures came in at $269.4 million (Q2 2026), -$103.4 million (Q1 2026), and -$27.8 million (Q4 2025), per Business Quant data.